Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis of overall survival.We randomly assigned patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had...